pyrazines has been researched along with Heart Failure in 127 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 35 (27.56) | 18.7374 |
| 1990's | 41 (32.28) | 18.2507 |
| 2000's | 19 (14.96) | 29.6817 |
| 2010's | 28 (22.05) | 24.3611 |
| 2020's | 4 (3.15) | 2.80 |
| Authors | Studies |
|---|---|
| Channick, R; Chin, KM; Du Roure, C; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Jenner, B; Lang, IM; McLaughlin, VV; Rosenkranz, S; Rubin, LJ; Sitbon, O; Tapson, V | 1 |
| Maeder, MT | 1 |
| Addison, D; Awan, F; Azali, L; Bhat, SA; Byrd, JC; Chen, ST; Gambril, J; Grever, M; Kalathoor, S; Kittai, A; Palettas, M; Rogers, KA; Rosen, L; Ruz, P; Wiczer, TE; Woyach, J; Zhao, Q | 1 |
| Cheng, H; Jiang, F; Wang, S; Wu, K; Xiao, B; Yin, K; Zhang, M; Zhou, Z | 1 |
| Guo, M; Hao, MH; Ma, XY; Sun, WP; Tang, Y; Zhu, HY | 1 |
| Carrie, D; Despas, F; Dumonteil, N; Galinier, M; Honton, B; Montastruc, JL; Pathak, A; Roussel, M; Rouvellat, C | 1 |
| Antonio, EL; Arruda-Junior, DF; Barreto, AL; Campos, LC; dos Santos, L; Girardi, AC; Krieger, JE; Mansur, AJ; Pereira, AC; Salles, TA; Tucci, PJ | 1 |
| Boutley, H; Karcher, G; Lacolley, P; Lhuillier, M; Louis, H; Marie, PY; Maskali, F; Poussier, S; Thornton, SN | 1 |
| Andrei, AC; Grady, KL | 1 |
| Akar, FG; Chaanine, AH; Hajjar, RJ; Jin, D; Kohlbrenner, E; Kovacic, JC; Nonnenmacher, M; Weber, T | 1 |
| Shah, BK; Sharma, LR; Subedi, A | 1 |
| Eurich, DT; McAlister, FA; Minhas-Sandhu, JK; Senthilselvan, A; Weir, DL | 1 |
| Bhatt, DL; Cavender, MA | 1 |
| Bian, HM; Ji, JW; Li, W; Li, Y; Song, P; Yin, QY; Zhu, Q | 1 |
| Chao, TF; Chen, SJ; Chen, TJ; Chiang, CE; Huang, CM; Lin, SJ; Liu, CJ; Wang, KL; Wu, CH; Yeh, CM | 1 |
| Canu, T; De Cobelli, F; Del Maschio, A; Esposito, A; Fragasso, G; Lattuada, G; Manzoni, G; Margonato, A; Perseghin, G; Salerno, A | 1 |
| Aota, Y; Gotoh, A; Hanyu, N; Honma, T; Kitagawa, N; Komatsu, N; Morisaki, M; Yokoyama, T | 1 |
| Armstrong, PW; Bethel, MA; Buse, JB; Engel, SS; Garg, J; Green, JB; Holman, RR; Josse, R; Kaufman, KD; Koglin, J; Korn, S; Lachin, JM; McGuire, DK; Pencina, MJ; Peterson, ED; Standl, E; Stein, PP; Suryawanshi, S; Van de Werf, F | 1 |
| Chen, L; Chen, YQ; Cheng, D; Li, W; Liu, J; Wang, TL; Wen, HM; Zhu, HH | 1 |
| Aydar, M; Kitai, T; Krittanawong, C; Sun, T | 1 |
| Gonullu, E; Hacihanefioglu, A; Tarkun, P | 1 |
| Foley, PW; Hamilton, MS; Leyva, F | 1 |
| Cas, LD; Cotter, G; Gheorghiade, M; Metra, M; Sabbah, HN; Teerlink, JR; Zacà, V | 1 |
| Bitter, M; Brunvand, MW | 1 |
| Horak, KM; Huang, W; Li, J; Liang, Q; Molkentin, JD; Su, H; Tang, M; Tian, Z; Wang, X | 1 |
| Bøtker, HE; Eiskjær, H; Gøtzsche, L; Halbirk, M; Møller, N; Nielsen, R; Nielsen, SS; Nielsen, TT; Nielsen-Kudsk, JE; Nørrelund, H; Schmitz, O; Wiggers, H | 1 |
| Carrier, L | 1 |
| Falk, RH | 1 |
| Gupta, A; Pandey, A; Sethi, S | 1 |
| Baerts, L; Bartunek, J; De Meester, I; Gomez, N; Lybaert, P; Mahmoudabady, M; Matheeussen, V; Mathieu, M; Mc Entee, K; Mendes Da Costa, A; Peace, A; Scharpé, S; Touihri, K; Vanderheyden, M | 1 |
| Domján, G; Gadó, K | 1 |
| Guo, L; Sun, Y; Wang, A; Xu, C | 1 |
| Bockorny, B; Bockorny, M; Bona, R; Chakravarty, S; Schulman, P | 1 |
| Buckley, CL; Horton, JS; Stokes, AJ | 1 |
| Sasayama, S | 5 |
| Battagliese, A; Bucciarelli Ducci, C; Celotto, A; De Luca, L; Fedele, F; Palombaro, GL; Proietti, P | 1 |
| Young, JB | 1 |
| Feldman, AM | 1 |
| Bertolet, BD | 1 |
| Chen, L; Deng, YL; Du, J; Huang, H; Lin, YZ; Xu, CX | 1 |
| Giaccone, G; Voortman, J | 1 |
| Eickhoff, JC | 1 |
| Dekhuijzen, PN; Heunks, LM; Jin, B; Li, YP; Linkels, M; Ottenheijm, CA; Pigmans, CJ; van Hees, HW | 1 |
| Berlind, S; Lundvall, O | 1 |
| Kremer, D | 1 |
| Hashimoto, K; Mori, T; Yabuuchi, Y; Yamashita, S | 1 |
| Khorunzhaia, LV; Merzon, KA; Tsoĭ, AN | 1 |
| Mor, R; Pitlik, S; Rosenfeld, JB | 1 |
| Huikko, M; Varjoranta, K; Viherkoski, M | 1 |
| Nordlie, KE; Søiland, C | 1 |
| Lachin, JM; Lan, KK; Rosenberger, WF | 1 |
| Harding, SE; Poole-Wilson, PA; Wynne, DG | 1 |
| Gheorghiade, M; Han, D; Tauke, J | 1 |
| Matsui, S; Matsumori, A; Sasayama, S; Shioi, T; Yamada, T | 1 |
| Feldman, AM; Strobeck, JE | 1 |
| Swedberg, K; Wedel, H | 1 |
| Neely, D | 1 |
| Grupp, G; Grupp, I; Schwartz, A | 1 |
| Bain, RP; Bristow, MR; Carson, PE; Feldman, AM; Gilbert, EM; Hendrix, GH; Parmley, WW; Pepine, CJ; Powers, ER; Strobeck, JE | 1 |
| Packer, M | 1 |
| Matsumori, A; Sasayama, S | 4 |
| Matsumori, A; Sasayama, S; Sato, Y | 1 |
| Bain, RP; Lachin, JM; Rosenberger, WF | 1 |
| Asanoi, H; Inoue, H | 1 |
| Becker, LC; Feldman, AM; Kasper, EK; Kass, DA; Van Anden, E; White, WB | 1 |
| Cheng, J; Kamiya, K; Kodama, I; Lee, JK; Suzuki, R; Toyama, J | 1 |
| Matsumori, A; Nose, Y; Ono, K; Sasayama, S; Sato, Y; Shioi, T | 1 |
| Marsh, JD; Vander Heide, RS | 1 |
| Cavusoglu, E; Frishman, WH; Klapholz, M | 1 |
| Cocca-Spofford, D; Dec, GW; DiSalvo, TG; Picard, MH; Scherrer-Crosbie, M; Semigran, MJ | 1 |
| Bourge, RC; Cohn, JN; DeMets, DL; Goldstein, SO; Gottlieb, SO; Greenberg, BH; Jaski, BE; Lorell, BH; McGrew, F; White, BG | 1 |
| Stevenson, LW | 1 |
| Borer, JS; Goldfine, SM; Herrold, EM; Ross, JS | 1 |
| Nicklas, JM; Pitt, B | 1 |
| Pritzker, MR | 1 |
| Alhaddad, IA | 1 |
| Bourge, R; Carson, P; Feldman, AM; Holubkov, R; Jaski, B; Loftus, S; Soran, O; White, BG; Young, JD | 1 |
| Lachin, JM | 1 |
| Cohn, JN; Feldman, AM; Holubkov, R; Reis, SE; White, BG; Young, JB | 1 |
| LeJemtel, TH | 1 |
| Deswal, A; Feldman, AM; Mann, DL; Petersen, NJ; White, BG; Young, JB | 1 |
| Deswal, A; Feldman, AM; Mann, DL; Petersen, NJ; White, BG | 1 |
| Poole-Wilson, PA; van Veldhuisen, DJ | 1 |
| Cheng, JH; Kamiya, K; Kodama, I | 1 |
| Anderson, S; Douglas, J; Wang, C | 1 |
| Counihan, TB; Dunne, A; Ryan, MF; Ryan, MP | 1 |
| Dewailly, P; Heim, J; Jaillard, J | 1 |
| Burkinshaw, L; Davidson, C; Morgan, DB | 1 |
| Baumann, JC; Braun, HD | 1 |
| Cohen, L; Kitzes, R; Rosenfeld, J | 1 |
| Sitprija, V; Stianrapapongs, P | 1 |
| Hayashida, W; Kawai, C; Kumada, T | 1 |
| Du, J; Yang, Z | 1 |
| Cui, LH; Duan, SF; Peng, W | 1 |
| Baughman, KL; Feldman, AM; Strobeck, JE | 1 |
| Baughman, KL; Becker, LC; Feldman, AM; Gottlieb, SH; Lee, WK; Strobeck, JE; Weiss, JL | 1 |
| English, TA; Gristwood, RW; Owen, DA; Sampford, KA; Wallwork, J | 1 |
| Asanoi, H; Ishizaka, S; Iuchi, K; Kameyama, T; Sasayama, S | 1 |
| Baughman, KL; Becker, LC; Feldman, AM; Llewellyn, MP | 1 |
| Hori, M; Inoue, M; Kodama, K; Kusukawa, R; Nonogi, H; Sakurai, T; Sasayama, S; Sugimoto, T; Takishima, T; Yasuda, H | 1 |
| Cohn, JN; Kubo, SH; Rector, TS; Strobeck, JE | 1 |
| Fukuda, K; Handa, S; Kawamura, Y; Nakamura, Y; Ogawa, S | 1 |
| Asanoi, H; Iuchi, K; Kameyama, T; Sasayama, S | 1 |
| Asanoi, H; Hori, M; Inoue, M; Kawai, C; Kodama, K; Sakurai, T; Sasayama, S | 1 |
| Higashino, Y; Hori, M; Inoue, M; Kamada, T; Kim, BH; Kodama, K; Matsubara, N; Naka, M; Nanto, S; Tsuneoka, Y | 1 |
| Gilly, R; Herne, N; Le Gall, F; Michaud, J; Roux, M | 1 |
| Hitzenberger, G | 1 |
| Nash, DT | 1 |
| Gerbaux, A; Hiltgen, M; Renais, J; Scebat, L | 1 |
| Bertrand, ME; Warembourg, H | 1 |
| Chapelle, M; Chiche, P | 1 |
| Demanet, JC; Hubert, C; Sevens-Rocmans, C | 1 |
| Bertrand, ME; Ginestet, A; Warembourg, H | 1 |
| Cox, JR; Porthouse, A | 1 |
| Heinz, N | 1 |
| Irvine, RO; McKean, WI | 1 |
| Koshikawa, S; Sasaoka, T | 1 |
22 review(s) available for pyrazines and Heart Failure
| Article | Year |
|---|---|
Bortezomib-induced acute congestive heart failure: a case report and review of literature.
Topics: Acute Disease; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Heart Failure; Humans; Male; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2014 |
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond.
Topics: Acute Disease; Cardiotonic Agents; Digoxin; Dobutamine; Etiocholanolone; Exercise Test; Heart Failure; Hemodynamics; Hospitals, Group Practice; Humans; Hydrazones; Prognosis; Pyrazines; Pyridazines; Quinolines; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Treatment Outcome; Urea; Vasodilator Agents | 2009 |
[AL amyloidosis].
Topics: Algorithms; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Heart Failure; Humans; Lenalidomide; Melphalan; Myocardium; Palliative Care; Patient Selection; Prognosis; Pyrazines; Quality of Life; Risk Assessment; Risk Factors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2012 |
Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature.
Topics: Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Heart Failure; Humans; Middle Aged; Multiple Myeloma; Myocarditis; Proteasome Inhibitors; Pyrazines | 2012 |
[Inotropic agents].
Topics: Adrenergic alpha-Agonists; Animals; Cardiotonic Agents; Clinical Trials as Topic; Digitalis Glycosides; Heart Failure; Humans; Pyrazines; Pyridazines; Quinolines | 2003 |
New positive inotropic agents in the treatment of left ventricular dysfunction.
Topics: Cardiotonic Agents; Diastole; Heart Failure; Humans; Hydrazones; Milrinone; Myocardial Ischemia; Phosphodiesterase Inhibitors; Pyrazines; Pyridazines; Quinolines; Simendan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2004 |
Clinical characteristics of vesnarinone.
Topics: Algorithms; Controlled Clinical Trials as Topic; Heart Failure; Humans; Multicenter Studies as Topic; Pyrazines; Quinolines; Time Factors | 2004 |
Optimising outcomes in end-stage heart failure: differences in therapeutic responses between diverse ethnic groups.
Topics: Asian People; Clinical Trials as Topic; Heart Failure; Humans; Pyrazines; Quinolines; Treatment Outcome; White People | 2004 |
Precautions for use and adverse effects of vesnarinone: potential mechanisms and future therapies.
Topics: Animals; Clinical Trials as Topic; Death, Sudden; Heart Failure; Humans; Monitoring, Physiologic; Multicenter Studies as Topic; Neutropenia; Pyrazines; Quinolines; Quinolones | 2004 |
Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure.
Topics: Adrenergic beta-Agonists; Cardiotonic Agents; Digoxin; Double-Blind Method; Drug Evaluation; Electrophysiology; Heart Failure; Hemodynamics; Humans; Myocardial Contraction; Neurosecretory Systems; Phosphodiesterase Inhibitors; Pyrazines; Quinolines | 1994 |
Quinolinone derivatives in the management of congestive heart failure.
Topics: Animals; Cardiotonic Agents; Heart Failure; Humans; Pyrazines; Quinolines; Quinolones | 1994 |
[Role of cytokines in etiological mechanism of congestive heart failure].
Topics: Cardiotonic Agents; Cytokines; Cytotoxicity, Immunologic; Heart Failure; Humans; Killer Cells, Natural; Pyrazines; Quinolines | 1995 |
Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy--lessons from animal experiments.
Topics: Adjuvants, Immunologic; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Cardiomyopathy, Dilated; Cardiotonic Agents; Cardiovirus Infections; Cytokines; Encephalomyocarditis virus; Heart Failure; Humans; Mice; Myocarditis; Prodrugs; Pyrazines; Quinolines; Tetrazoles; Tumor Necrosis Factor-alpha | 1995 |
Vesnarinone: a potential cytokine inhibitor.
Topics: Adjuvants, Immunologic; Animals; Cytokines; Heart Failure; Humans; Pyrazines; Quinolines | 1996 |
Ion channel blockers in the treatment of chronic heart failure.
Topics: Amiodarone; Animals; Calcium Channel Blockers; Chronic Disease; Heart Failure; Humans; Potassium Channel Blockers; Pyrazines; Quinolines | 1996 |
Inotropic agents in the treatment of heart failure: despair or hope?
Topics: Adrenergic beta-Agonists; Cardiotonic Agents; Cyclic AMP; Digitalis; Heart Failure; Humans; Plants, Medicinal; Plants, Toxic; Prognosis; Pyrazines; Pyridazines; Quinolines | 1997 |
Heart failure: clinical implications of recent trials.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Diuretics; Heart Failure; Humans; Pyrazines; Quinolines | 1994 |
Worst-rank score analysis with informatively missing observations in clinical trials.
Topics: Cardiotonic Agents; Data Interpretation, Statistical; Follow-Up Studies; Heart Failure; Humans; Pyrazines; Quinolines; Randomized Controlled Trials as Topic | 1999 |
Review of a dose-dependent increase in mortality with vesnarinone among patients with severe heart failure.
Topics: Cardiotonic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Heart Failure; Humans; Pyrazines; Quinolines; Survival Analysis | 1999 |
The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure.
Topics: Bosentan; Cardiovascular Agents; Deoxyepinephrine; Heart Failure; Humans; Imidazoles; Mibefradil; Pyrazines; Quinolines; Sulfonamides; Xamoterol | 2001 |
Carvedilol and vesnarinone: new antiarrhythmic approach in heart failure therapy.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Calcium Channels, L-Type; Carbazoles; Cardiotonic Agents; Carvedilol; Heart Failure; Humans; Potassium Channels; Propanolamines; Pyrazines; Quinolines | 2001 |
[New oral drugs for the treatment of congestive heart failure].
Topics: Administration, Oral; Cardiotonic Agents; Deoxyepinephrine; Ethanolamines; Heart Failure; Humans; Phosphodiesterase Inhibitors; Piperidines; Propanolamines; Pyrazines; Quinolines; Quinolones; Vasodilator Agents; Xamoterol | 1992 |
27 trial(s) available for pyrazines and Heart Failure
| Article | Year |
|---|---|
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study.
Topics: Acetamides; Antihypertensive Agents; Comorbidity; Double-Blind Method; Heart Failure; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Pyrazines | 2022 |
Visualization and dynamics of multidimensional health-related quality-of-life-adjusted overall survival: a new analytic approach.
Topics: Cardiotonic Agents; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pyrazines; Quality of Life; Quality-Adjusted Life Years; Quinolines; Sickness Impact Profile; Stochastic Processes; Surveys and Questionnaires; Treatment Outcome; Ventricular Function, Left | 2014 |
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Glycated Hemoglobin; Heart Diseases; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Pyrazines; Sitagliptin Phosphate; Triazoles | 2015 |
Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Chronic Disease; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fatty Acids, Nonesterified; Female; Heart; Heart Failure; Humans; Hypolipidemic Agents; Male; Metabolism; Middle Aged; Pyrazines; Stroke Volume; Vascular Resistance | 2010 |
[Treatment of cardiac failure with diuretics. A double-blind study comparing a fixed combination of hydrochlorothiazide/amiloride and furosemide plus potassium substitution].
Topics: Adult; Aged; Amiloride; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Furosemide; Heart Failure; Humans; Hydrochlorothiazide; Middle Aged; Potassium; Pyrazines | 1983 |
The effect of amiloride/hydrochlorothiazide combination vs furosemide plus potassium supplementation in the treatment of oedema of cardiac origin.
Topics: Adult; Aged; Amiloride; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Edema, Cardiac; Female; Furosemide; Heart Failure; Humans; Hydrochlorothiazide; Male; Middle Aged; Potassium Chloride; Pyrazines | 1981 |
[Moduretic in the treatment of cardiac failure].
Topics: Aged; Amiloride; Clinical Trials as Topic; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Humans; Hydrochlorothiazide; Male; Middle Aged; Pyrazines | 1981 |
Amiloride--a potassium-sparing diuretic.
Topics: Amiloride; Clinical Trials as Topic; Heart Failure; Humans; Hypertension; Hypokalemia; Pyrazines | 1981 |
Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure.
Topics: Adrenergic beta-Agonists; Cardiotonic Agents; Digoxin; Double-Blind Method; Drug Evaluation; Electrophysiology; Heart Failure; Hemodynamics; Humans; Myocardial Contraction; Neurosecretory Systems; Phosphodiesterase Inhibitors; Pyrazines; Quinolines | 1994 |
Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group.
Topics: Adult; Aged; Aged, 80 and over; Cardiotonic Agents; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Morbidity; Proportional Hazards Models; Prospective Studies; Pyrazines; Quality of Life; Quinolines | 1993 |
Dose dependence of chronic positive inotropic effect of vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy.
Topics: Administration, Oral; Cardiomyopathies; Cardiotonic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Heart Failure; Hemodynamics; Humans; Pyrazines; Quinolines; Regression Analysis; Ventricular Function | 1996 |
Effect of vesnarinone on cardiac function in patients with severe congestive heart failure.
Topics: Aged; Cardiotonic Agents; Echocardiography; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Pyrazines; Quinolines; Ventricular Function, Left | 1998 |
A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.
Topics: Aged; Agranulocytosis; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Cardiotonic Agents; Death, Sudden; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Pyrazines; Quality of Life; Quinolines; Survival Analysis | 1998 |
Effect of inotrope withdrawal on morbidity and mortality in patients with chronic heart failure: results of the vesnarinone trial withdrawal substudy. Vest Withdrawal Substudy Group.
Topics: Cardiotonic Agents; Cause of Death; Chronic Disease; Disease Progression; Follow-Up Studies; Heart Failure; Humans; Middle Aged; Myocardial Contraction; Pyrazines; Quinolines; Retrospective Studies; Substance Withdrawal Syndrome; Survival Rate | 1999 |
Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the Vesnarinone Trial.
Topics: Cardiotonic Agents; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Heart Failure; Humans; Interleukin-6; Male; Middle Aged; Pyrazines; Quinolines; Receptors, Cytokine; Receptors, Interleukin-6; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor-alpha | 2001 |
The effects of potassium supplements, spironolactone of amiloride on the potassium status of patients with heart failure.
Topics: Adult; Aged; Amiloride; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Potassium; Potassium Deficiency; Pyrazines; Spironolactone | 1978 |
[Potassium-saving saluretic treatment of hypertension and edematous heart decompensation with Moduretik].
Topics: Adult; Aged; Amiloride; Clinical Trials as Topic; Drug Combinations; Edema, Cardiac; Female; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Potassium; Pyrazines | 1976 |
[Effect of combined treatment with hydrochlorothiazide and amiloride on serum and urinary potassium].
Topics: Amiloride; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Hydrochlorothiazide; Hypokalemia; Potassium; Pyrazines | 1975 |
Oral milrinone in severe chronic heart failure.
Topics: Cardiotonic Agents; Heart Failure; Humans; Milrinone; Pyrazines; Pyridones; Quinolines | 1992 |
Usefulness of OPC-8212, a quinolinone derivative, for chronic congestive heart failure in patients with ischemic heart disease or idiopathic dilated cardiomyopathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Cardiotonic Agents; Coronary Disease; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Physical Exertion; Pyrazines; Quality of Life; Quinolines | 1991 |
A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. OPC-8212 Multicenter Research Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Pressure; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Echocardiography; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Pyrazines; Quality of Life; Quinolines; Severity of Illness Index | 1990 |
Sustained inotropic effects of a new cardiotonic agent. OPC-8212 in patients with chronic heart failure.
Topics: Adult; Aged; Cardiotonic Agents; Clinical Trials as Topic; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Contraction; Pyrazines; Quinolines; Stimulation, Chemical; Stroke Volume; Time Factors | 1989 |
Evaluation of a new inotropic agent, OPC-8212, in patients with dilated cardiomyopathy and heart failure.
Topics: Adult; Cardiomyopathy, Dilated; Cardiotonic Agents; Clinical Trials as Topic; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Pyrazines; Quinolines; Respiratory Function Tests | 1988 |
A multicenter study of a new inotropic agent, piperanometozine (OPC-8212) in congestive heart failure: clinical improvement during short-term treatment.
Topics: Aged; Cardiotonic Agents; Female; Heart Failure; Humans; Male; Middle Aged; Pyrazines; Quinolines | 1987 |
[Effect of amiloride on potassium loss induced by hydrochlorothiazide].
Topics: Amiloride; Chlorides; Diuresis; Drug Interactions; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydrochlorothiazide; Hydrogen-Ion Concentration; Hypokalemia; Male; Middle Aged; Natriuresis; Potassium; Pyrazines; Statistics as Topic | 1974 |
[Treatment of cardiac edema with a new diuretic (combination of amiloride hydrochlorate and hydrochlorothiazide)].
Topics: Adult; Aged; Amiloride; Clinical Trials as Topic; Diuretics; Drug Combinations; Female; Heart Failure; Humans; Hydrochlorothiazide; Male; Middle Aged; Natriuresis; Potassium; Pyrazines; Sodium | 1974 |
[Course of diuresis in heart failure during ethacrynic acid and amiloride therapy].
Topics: Chlorides; Diuresis; Diuretics; Ethacrynic Acid; Heart Failure; Humans; Hyperkalemia; Natriuresis; Potassium; Pyrazines | 1971 |
79 other study(ies) available for pyrazines and Heart Failure
| Article | Year |
|---|---|
Selexipag and the pulmonary hypertension continuum.
Topics: Acetamides; Heart Failure; Humans; Hypertension, Pulmonary; Pyrazines | 2022 |
Ventricular arrhythmias and sudden death events following acalabrutinib initiation.
Topics: Aged; Arrhythmias, Cardiac; Benzamides; Death, Sudden; Heart Failure; Humans; Pyrazines | 2022 |
The mechanosensitive Piezo1 channel mediates heart mechano-chemo transduction.
Topics: Animals; Arrhythmias, Cardiac; Calcium; Calcium Signaling; Cardiomyopathies; Gene Deletion; Heart Failure; Heart Function Tests; Homeostasis; Ion Channels; Mechanotransduction, Cellular; Mice, Knockout; Myocardium; Myocytes, Cardiac; Organ Specificity; Pyrazines; Reactive Oxygen Species; Thiadiazoles; Up-Regulation | 2021 |
Oltipraz attenuates the progression of heart failure in rats through inhibiting oxidative stress and inflammatory response.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Cytokines; Disease Models, Animal; Fibrosis; Heart Failure; Inflammation Mediators; Isoproterenol; Myocytes, Cardiac; Oxidative Stress; Pyrazines; Rats, Sprague-Dawley; Recovery of Function; Thiones; Thiophenes; Ventricular Function, Left; Ventricular Remodeling | 2018 |
Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Databases, Pharmaceutical; France; Heart Failure; Heart Function Tests; Humans; Male; Middle Aged; Multiple Myeloma; Pharmacovigilance; Pyrazines; Treatment Outcome | 2014 |
Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure.
Topics: Adult; Aged; Animals; Apoptosis; Biomarkers; Case-Control Studies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Female; Glucagon-Like Peptide 1; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Myocardium; Natriuretic Peptide, Brain; Pulmonary Edema; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Up-Regulation; Ventricular Function, Left; Ventricular Remodeling | 2013 |
Assessment of the early stage of cardiac remodeling of spontaneously hypertensive heart failure rats using the quantitative 3-dimensional analysis provided by acipimox-enhanced FDG-PET.
Topics: Animals; Arterial Pressure; Cardiac Catheterization; Disease Models, Animal; Fibrosis; Fluorodeoxyglucose F18; Heart Failure; Heart Ventricles; Hypertension; Imaging, Three-Dimensional; Lipid Metabolism; Male; Positron-Emission Tomography; Predictive Value of Tests; Pyrazines; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke Volume; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2014 |
Effect of bortezomib on the efficacy of AAV9.SERCA2a treatment to preserve cardiac function in a rat pressure-overload model of heart failure.
Topics: Animals; Boronic Acids; Bortezomib; Dependovirus; Disease Models, Animal; Genetic Therapy; Genetic Vectors; Heart Failure; Humans; Myocardium; Myocytes, Cardiac; Pyrazines; Rats; Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2014 |
Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Pyrazines; Retrospective Studies; Risk Factors; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure?
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Humans; Male; Pyrazines; Triazoles | 2014 |
Liguzinediol improved the heart function and inhibited myocardial cell apoptosis in rats with heart failure.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Doxorubicin; Gene Expression; Heart; Heart Failure; Male; Myocytes, Cardiac; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Rats; Rats, Sprague-Dawley | 2014 |
Sitagliptin and the risk of hospitalization for heart failure: a population-based study.
Topics: Diabetes Mellitus; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Morbidity; Population Surveillance; Propensity Score; Pyrazines; Retrospective Studies; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Taiwan; Triazoles | 2014 |
Effects of short-term manipulation of serum FFA concentrations on left ventricular energy metabolism and function in patients with heart failure: no association with circulating bio-markers of inflammation.
Topics: Adipokines; Adult; Aged; Biomarkers; Energy Metabolism; Fatty Acids, Nonesterified; Heart Failure; Heart Ventricles; Humans; Hypolipidemic Agents; Inflammation; Insulin; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Pyrazines; Tumor Necrosis Factor-alpha; Ventricular Function, Left | 2015 |
[Bortezomib-associated acute congestive heart failure in a patient with multiple myeloma].
Topics: Acute Disease; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Electrocardiography; Female; Heart Failure; Humans; Multiple Myeloma; Pyrazines | 2015 |
Synthesis and positive inotropic activity evaluation of liguzinediol metabolites.
Topics: Animals; Blood Pressure; Cardiotonic Agents; Heart Failure; Heart Rate; Male; Muscle Contraction; Pyrazines; Rats; Rats, Sprague-Dawley | 2016 |
Sitagliptin and Risk of Heart Failure in Patients With Type 2 Diabetes: A Meta-Analysis.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Humans; Pyrazines; Risk; Sitagliptin Phosphate | 2016 |
Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib.
Topics: Acute Disease; Antineoplastic Agents; Boronic Acids; Bortezomib; Heart Failure; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2008 |
Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Female; Fibrosis; Gadolinium; Heart Failure; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Myocardium; Pyrazines | 2010 |
Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant.
Topics: Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Pyrazines; Recurrence; Transplantation, Autologous | 2010 |
Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts.
Topics: Animals; Boronic Acids; Bortezomib; Calcineurin; Cells, Cultured; Desmin; Heart Failure; Mice; Mice, Transgenic; Models, Animal; Myocytes, Cardiac; NFATC Transcription Factors; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Stress, Physiological | 2010 |
Too much of a good thing is bad: proteasome inhibition induces stressed hearts to fail.
Topics: Adaptation, Physiological; Animals; Boronic Acids; Bortezomib; Calcineurin; Dose-Response Relationship, Drug; Heart Failure; Hypertrophy, Left Ventricular; Mice; Models, Animal; Myocytes, Cardiac; NFATC Transcription Factors; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Stress, Physiological; Ubiquitin | 2010 |
Cardiac amyloidosis: a treatable disease, often overlooked.
Topics: Adrenergic beta-Antagonists; Amyloidosis; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Boronic Acids; Bortezomib; Calcium Channel Blockers; Dexamethasone; Diuretics; Drug Therapy, Combination; Female; Heart Failure; Humans; Lenalidomide; Melphalan; Middle Aged; Myocardium; Prealbumin; Pyrazines; Severity of Illness Index; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Bortezomib-induced congestive cardiac failure in a patient with multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Heart Failure; Humans; Multiple Myeloma; Pyrazines | 2012 |
Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure.
Topics: Animals; Calmodulin; Cardiac Pacing, Artificial; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Female; Glomerular Filtration Rate; Heart Failure; Heart Rate; Hemodynamics; Interleukin-6; Natriuretic Peptide, Brain; Pyrazines; Sitagliptin Phosphate; Sodium-Calcium Exchanger; Swine; Triazoles | 2012 |
Evaluation of antioxidant and immunity function of tetramethylpyrazine phosphate tablets in vivo.
Topics: Animals; Antioxidants; Blood Pressure; Body Weight; Cardiotonic Agents; Catalase; Glutathione Peroxidase; Heart; Heart Failure; Interleukin-6; Isoproterenol; Malondialdehyde; Organ Size; Organophosphates; Oxidative Stress; Pyrazines; Rats; Rats, Wistar; Superoxide Dismutase; Tablets; Tumor Necrosis Factor-alpha; Ventricular Function, Left | 2012 |
Successful TRPV1 antagonist treatment for cardiac hypertrophy and heart failure in mice.
Topics: Animals; Apoptosis; Cardiomegaly; Disease Models, Animal; Heart Failure; Humans; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Natriuretic Peptide, Brain; Pyrazines; Pyridines; TRPV Cation Channels | 2013 |
Inotropic agents and immune modulation.
Topics: Adjuvants, Immunologic; Animals; Cardiotonic Agents; Clinical Trials as Topic; Cytokines; Heart Failure; Humans; Myocardium; Phosphodiesterase Inhibitors; Pyrazines; Pyridazines; Quality of Life; Quinolines; Time Factors | 2002 |
The best of times, the worst of times: the wealth and poverty of heart failure pharmacotherapies: is there a role for vesnarinone?
Topics: Clinical Trials as Topic; Drug Therapy; Forecasting; Heart Failure; Humans; Pyrazines; Quinolines; Quinolones; Socioeconomic Factors; Time Factors | 2004 |
[Effects of tetramethylpyrazine on fibrosis of atrial tissue and atrial fibrillation in a canine model of congestive heart failure induced by ventricular tachypacing].
Topics: Animals; Atrial Fibrillation; Cardiac Pacing, Artificial; Dogs; Female; Fibrosis; Heart Atria; Heart Failure; Male; Pyrazines; Random Allocation | 2006 |
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Comorbidity; Deoxycytidine; Gemcitabine; Heart Failure; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Risk Factors; Ventricular Dysfunction, Left | 2006 |
Placebo effect-adjusted assessment of quality of life in placebo-controlled clinical trials.
Topics: Algorithms; Biometry; Cardiotonic Agents; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Endpoint Determination; Heart Failure; Humans; Likelihood Functions; Models, Statistical; Monte Carlo Method; Multicenter Studies as Topic; Placebo Effect; Pyrazines; Quality of Life; Quinolines; Randomized Controlled Trials as Topic | 2008 |
Proteasome inhibition improves diaphragm function in congestive heart failure rats.
Topics: Animals; Boronic Acids; Bortezomib; Caspase 3; Diaphragm; Heart Failure; Male; Myosin Heavy Chains; Myosins; Proteasome Inhibitors; Pyrazines; Rats; Rats, Wistar; Ubiquitination | 2008 |
Clinical trial of a potassium-sparing saluretic pyrazine derivative (MK-870).
Topics: Adult; Aged; Carbon Dioxide; Chlorides; Creatine; Diuretics; Edema; Female; Heart Failure; Humans; Liver Cirrhosis; Male; Middle Aged; Potassium; Pyrazines; Sodium; Uric Acid | 1967 |
Positive inotropic effect of 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212) in the dog with experimentally-induced right-sided heart failure.
Topics: Administration, Oral; Aminopyridines; Amrinone; Animals; Blood Pressure; Cardiotonic Agents; Dobutamine; Dogs; Dose-Response Relationship, Drug; Heart Failure; Heart Rate; Injections, Intravenous; Male; Myocardial Contraction; Pyrazines; Quinolines | 1984 |
[Use of antipotassiuretic diuretic amiloride in patients with chronic cardiac failure].
Topics: Amiloride; Chronic Disease; Diuresis; Heart Failure; Humans; Potassium; Potassium Deficiency; Pyrazines | 1983 |
Indomethacin- and Moduretic--induced hyperkalemia.
Topics: Aged; Amiloride; Diabetes Complications; Diabetes Mellitus; Drug Combinations; Drug Interactions; Female; Heart Failure; Humans; Hydrochlorothiazide; Hyperkalemia; Indomethacin; Pyrazines | 1983 |
Sequential monitoring of survival data with the Wilcoxon statistic.
Topics: Biometry; Cardiotonic Agents; Clinical Trials as Topic; Follow-Up Studies; Heart Failure; Humans; Life Tables; Models, Statistical; Pyrazines; Quinolines; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Time Factors | 1995 |
Incomplete reversal of beta-adrenoceptor desensitization in human and guinea-pig cardiomyocytes by cyclic nucleotide phosphodiesterase inhibitors.
Topics: 1-Methyl-3-isobutylxanthine; 2',3'-Cyclic-Nucleotide Phosphodiesterases; Adrenergic beta-Antagonists; Animals; Cardiotonic Agents; Guanidines; Guinea Pigs; Heart; Heart Failure; Humans; In Vitro Techniques; Isoproterenol; Male; Myocardial Contraction; Myocardium; Norepinephrine; Pyrazines; Pyridazines | 1993 |
Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure.
Topics: Blood; Cardiotonic Agents; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Heart Failure; Humans; In Vitro Techniques; Male; Middle Aged; Pyrazines; Quinolines | 1994 |
Vesnarinone for heart failure.
Topics: Cardiotonic Agents; Heart Failure; Humans; Pyrazines; Quinolines | 1994 |
Vesnarinone for heart failure.
Topics: Cardiotonic Agents; Heart Failure; Humans; Pyrazines; Quinolines | 1994 |
Vesnarinone for heart failure.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Myocardial Contraction; Pyrazines; Quinolines; Stimulation, Chemical | 1994 |
The search for the ideal positive inotropic agent.
Topics: Cardiotonic Agents; Heart Failure; Humans; Myocardial Contraction; Pyrazines; Quinolines | 1993 |
Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Amrinone; Cardiotonic Agents; Cell Adhesion; Cells, Cultured; Colforsin; Cyclic AMP; Cytokines; Depression, Chemical; E-Selectin; Endothelium, Vascular; Gene Expression Regulation; Heart Failure; Hematopoietic Cell Growth Factors; Humans; Intercellular Adhesion Molecule-1; Interleukin-1; Monocytes; Neutropenia; Pyrazines; Quinolines; Tumor Necrosis Factor-alpha; Umbilical Veins; Vascular Cell Adhesion Molecule-1 | 1995 |
Nonparametric test of stochastic ordering for multiple longitudinal measures.
Topics: Cardiotonic Agents; Double-Blind Method; Heart Failure; Humans; Longitudinal Studies; Multicenter Studies as Topic; Multivariate Analysis; Pyrazines; Quinolines; Randomized Controlled Trials as Topic; Research Design; Statistics, Nonparametric; Stochastic Processes | 1995 |
Role of cytokines in the syndrome of heart failure.
Topics: Adrenergic beta-Agonists; Amrinone; Animals; Cardiotonic Agents; Cytokines; Heart Failure; Humans; Killer Cells, Natural; Myocarditis; Phosphodiesterase Inhibitors; Pyrazines; Quinolines; Tumor Necrosis Factor-alpha | 1996 |
Positive inotropic agents: a double-edged sword for chronic heart failure.
Topics: Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Heart Failure; Humans; Pyrazines; Pyridazines; Quinolines | 1996 |
Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; 8-Bromo Cyclic Adenosine Monophosphate; Amrinone; Cells, Cultured; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 5; Heart Failure; Humans; Interleukin-1; Interleukin-6; Kinetics; Leukocytes, Mononuclear; Lipopolysaccharides; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperidines; Pyrazines; Pyridazines; Quinazolines; Quinolines; Tumor Necrosis Factor-alpha | 1996 |
Through the looking glass: a positive inotropic drug and ischemic preconditioning.
Topics: 5'-Nucleotidase; Adenosine; Animals; Cardiotonic Agents; Dogs; Drug Approval; Enzyme Activation; Heart Failure; Humans; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Myocardium; Neutropenia; Protein Kinase C; Pyrazines; Quinolines; Second Messenger Systems | 1997 |
[Drug therapy of congestive heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiotonic Agents; Digitalis; Diuretics; Heart Failure; Humans; Phosphodiesterase Inhibitors; Plants, Medicinal; Plants, Toxic; Pyrazines; Quinolines; Vasodilator Agents | 1997 |
Vesnarinone: a new inotropic agent for treating congestive heart failure.
Topics: Cardiotonic Agents; Clinical Trials as Topic; Cytokines; Heart Failure; Hemodynamics; Humans; Pyrazines; Quinolines; Vascular Resistance | 1995 |
Inotropic therapy for heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Death, Sudden; Disease Progression; Diuretics; Drug Therapy, Combination; Heart Failure; Humans; Pyrazines; Quinolines | 1998 |
Differential response to vesnarinone by cardiac fibroblasts isolated from normal and aortic regurgitant hearts.
Topics: Animals; Aortic Valve Insufficiency; Cardiotonic Agents; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Fibroblasts; Heart; Heart Failure; Pyrazines; Quinolines; Rabbits | 1998 |
Severe heart failure: balancing length and quality of life.
Topics: Amrinone; Cardiotonic Agents; Heart Failure; Humans; Milrinone; Phosphodiesterase Inhibitors; Pyrazines; Quality of Life; Quinolines | 1999 |
Chronic heart failure and the quality of life.
Topics: Cardiotonic Agents; Heart Failure; Humans; Milrinone; Palliative Care; Pyrazines; Quality of Life; Quinolines | 1999 |
Chronic heart failure and the quality of life.
Topics: Cardiotonic Agents; Heart Failure; Humans; Pyrazines; Quality of Life; Quinolines | 1999 |
Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies.
Topics: Aged; Cardiotonic Agents; Estradiol Congeners; Estrogen Replacement Therapy; Female; Heart Failure; Humans; Middle Aged; Multicenter Studies as Topic; Pyrazines; Quinolines; Randomized Controlled Trials as Topic; Survival Analysis | 2000 |
Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).
Topics: Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Antigens, CD; Biomarkers; Cardiotonic Agents; Clinical Trials as Topic; Cohort Studies; Cytokines; Demography; Female; Heart Failure; Humans; Interleukin-6; Male; Middle Aged; Multicenter Studies as Topic; Predictive Value of Tests; Pyrazines; Quinolines; Receptors, Cytokine; Receptors, Interleukin-6; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Severity of Illness Index; Sex Distribution; Sex Factors; Survival Analysis; Tumor Necrosis Factor-alpha | 2001 |
Item response models for joint analysis of quality of life and survival.
Topics: Area Under Curve; Cardiotonic Agents; Clinical Trials as Topic; Computer Simulation; Heart Failure; Humans; Markov Chains; Models, Biological; Monte Carlo Method; Proportional Hazards Models; Pyrazines; Quality of Life; Quinolines; Surveys and Questionnaires; Survival Analysis | 2002 |
Time-related changes in urinary aldosterone and electrolyte excretion during amiloride administration to congestive heart failure patients [proceedings].
Topics: Aldosterone; Amiloride; Electrolytes; Heart Failure; Humans; Pyrazines; Time Factors | 1979 |
[Hyperkalemia caused by hyporeninism: role of the hydrochlorothiazide-amiloride combination].
Topics: Aged; Aldosterone; Amiloride; Diabetes Complications; Female; Heart Failure; Humans; Hydrochlorothiazide; Hyperkalemia; Pyrazines; Renin | 1977 |
Diuretic effect of combined thiazide and amiloride.
Topics: Adult; Amiloride; Diuretics; Drug Combinations; Drug Therapy, Combination; Heart Failure; Humans; Hydrochlorothiazide; Middle Aged; Pyrazines | 1975 |
[Effect of Chinese-made vesnarinone on experimental heart failure of dog].
Topics: Animals; Cardiac Output; Cardiotonic Agents; Dogs; Female; Heart Failure; Hemodynamics; Male; Myocardial Contraction; Pentobarbital; Pyrazines; Quinolines; Stimulation, Chemical | 1992 |
Effects of sustained ligustrazine on hemorrheology in patients with chronic pulmonary heart disease.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aged, 80 and over; Blood Viscosity; Female; Fibrinolytic Agents; Heart Failure; Hematocrit; Humans; Male; Middle Aged; Pulmonary Heart Disease; Pyrazines; Thromboxane B2 | 1992 |
Analysis of responses to a selective phosphodiesterase III inhibitor, SK&F 94120, on isolated myocardium, including human ventricular myocardium from "end-stage" failure patients.
Topics: Animals; Carbachol; Cats; Female; Guinea Pigs; Heart Failure; Heart Ventricles; Humans; In Vitro Techniques; Isoproterenol; Male; Myocardial Contraction; Myocardium; Phosphodiesterase Inhibitors; Pyrazines; Swine | 1987 |
OPC-8212 in the treatment of congestive heart failure: results of a pilot study.
Topics: Aged; Cardiotonic Agents; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Pilot Projects; Pyrazines; Quinolines | 1988 |
[Usefulness of OPC-8212, an inotropic agent, in patients with chronic congestive heart failure--a multiple dose evaluation on its effect and arrhythmogenesis].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiotonic Agents; Drug Evaluation; Female; Heart Failure; Humans; Male; Middle Aged; Pyrazines; Quinolines | 1988 |
Acute hemodynamic effects of a new inotropic agent (OPC-8212) in patients with congestive heart failure.
Topics: Adult; Aged; Cardiac Output; Cardiotonic Agents; Drug Evaluation; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Pyrazines; Quinolines; Stroke Volume | 1987 |
Acute hemodynamic effects of a new inotropic agent, OPC-8212, on severe congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Cardiac Output; Cardiomyopathy, Dilated; Cardiotonic Agents; Coronary Disease; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Myocardial Contraction; Myocarditis; Pyrazines; Quinolines | 1986 |
Oral OPC-8212 for the treatment of congestive heart failure: hemodynamic improvement and increased exercise capacity.
Topics: Administration, Oral; Aged; Blood Pressure; Cardiotonic Agents; Female; Heart Failure; Heart Rate; Hemodynamics; Humans; Male; Middle Aged; Physical Exertion; Pyrazines; Quinolines; Radionuclide Imaging; Stroke Volume | 1986 |
[Clinical study of amiloride hydrochloride, a diuretic with low potassium loss].
Topics: Arrhythmias, Cardiac; Blood Urea Nitrogen; Cardiac Complexes, Premature; Diuretics; Drug Synergism; Edema; Ethacrynic Acid; Furosemide; Heart Failure; Humans; Hydrochlorothiazide; Liver Cirrhosis; Potassium; Pyrazines; Sodium | 1970 |
[Therapy of cardiac edema with a combination of hydrochlorthiazide and amiloride-HCl (author's transl)].
Topics: Alkalosis; Diuretics; Drug Combinations; Electrolytes; Heart Failure; Hydrochlorothiazide; Hypokalemia; Long-Term Care; Pyrazines; Sodium | 1973 |
A clinical study of Co-hydroDiuril a combination of an antikaliuretic (amiloride) and hydrochlorothiazide.
Topics: Adult; Aged; Amiloride; Blood Pressure; Blood Urea Nitrogen; Body Weight; Diuretics; Drug Combinations; Drug Eruptions; Female; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Potassium; Pyrazines; Urinary Incontinence; Vertigo | 1972 |
[The treatment of cardiac edemas with a new diuretic (combination of amiloride and hydrochlorothiazide)].
Topics: Adult; Aged; Amiloride; Diuretics; Female; Heart Failure; Humans; Hydrochlorothiazide; Male; Middle Aged; Pyrazines | 1973 |
[Potassium depletion in cardiology. Action of amiloride, a potassium sparing diuretic].
Topics: Adult; Aged; Amiloride; Arrhythmias, Cardiac; Coronary Disease; Digitalis Glycosides; Diuretics; Female; Heart Diseases; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Potassium Deficiency; Pyrazines | 1973 |
[Comparison of the combination of hydrochlorothiazide and amiloride (Moduretic) and furosemide in the treatment of cardiac edema].
Topics: Aged; Amiloride; Diuretics; Drug Combinations; Female; Furosemide; Heart Failure; Humans; Hydrochlorothiazide; Male; Middle Aged; Pyrazines | 1973 |
Effect of amiloride and hydrochlorothiazide on body fluids and electrolytes in geriatric patients with congestive cardiac failure.
Topics: Aged; Amiloride; Body Fluids; Diuretics; Electrolytes; Heart Failure; Humans; Hydrochlorothiazide; Potassium; Pyrazines; Radioisotope Dilution Technique; Sodium; Water-Electrolyte Balance | 1974 |
Evaluation of amiloride combined with hydrochlorothiazide in the treatment of congestive heart failure.
Topics: Aged; Amidines; Body Weight; Diuretics; Drug Synergism; Female; Heart Failure; Humans; Hydrochlorothiazide; Male; Middle Aged; Potassium; Pyrazines; Sodium; Time Factors; Urea | 1970 |
Clinical evaluations of a combined application of amiloride (MK-870) and thiazide.
Topics: Adult; Blood Pressure; Diuretics; Female; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Kidney Function Tests; Liver Cirrhosis; Male; Middle Aged; Nephrotic Syndrome; Potassium; Pyrazines; Sodium | 1969 |